Assenagon Asset Management S.A. Purchases 1,192,489 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Assenagon Asset Management S.A. raised its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 141.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,037,896 shares of the biopharmaceutical company’s stock after purchasing an additional 1,192,489 shares during the quarter. Assenagon Asset Management S.A.’s holdings in Amicus Therapeutics were worth $21,765,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Blue Trust Inc. grew its stake in shares of Amicus Therapeutics by 1,705.4% during the third quarter. Blue Trust Inc. now owns 2,997 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 2,831 shares during the last quarter. Headlands Technologies LLC purchased a new position in Amicus Therapeutics during the 2nd quarter valued at $89,000. Sage Capital Advisors llc purchased a new position in Amicus Therapeutics during the 2nd quarter valued at $103,000. EntryPoint Capital LLC grew its position in Amicus Therapeutics by 278.8% in the 1st quarter. EntryPoint Capital LLC now owns 13,218 shares of the biopharmaceutical company’s stock valued at $156,000 after acquiring an additional 9,729 shares during the last quarter. Finally, Sanctuary Advisors LLC purchased a new stake in Amicus Therapeutics in the second quarter worth $138,000.

Amicus Therapeutics Stock Performance

Shares of Amicus Therapeutics stock opened at $11.69 on Friday. The company has a market capitalization of $3.46 billion, a PE ratio of -23.86 and a beta of 0.69. The company has a 50-day simple moving average of $11.19 and a two-hundred day simple moving average of $10.57. Amicus Therapeutics, Inc. has a one year low of $9.02 and a one year high of $14.57. The company has a debt-to-equity ratio of 2.93, a quick ratio of 2.26 and a current ratio of 2.75.

Amicus Therapeutics (NASDAQ:FOLD) last posted its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.05) EPS for the quarter, meeting analysts’ consensus estimates of ($0.05). The company had revenue of $126.67 million during the quarter, compared to analysts’ expectations of $121.21 million. Amicus Therapeutics had a negative net margin of 26.23% and a negative return on equity of 41.47%. Amicus Therapeutics’s revenue for the quarter was up 34.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.15) earnings per share. Research analysts expect that Amicus Therapeutics, Inc. will post -0.07 EPS for the current fiscal year.

Insider Buying and Selling

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of the firm’s stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $10.34, for a total value of $77,550.00. Following the completion of the sale, the chief executive officer now owns 886,654 shares of the company’s stock, valued at approximately $9,168,002.36. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold a total of 22,500 shares of company stock worth $244,875 in the last ninety days. 2.20% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on FOLD shares. Needham & Company LLC reissued a “hold” rating on shares of Amicus Therapeutics in a research note on Friday, August 9th. Morgan Stanley decreased their price target on shares of Amicus Therapeutics from $19.00 to $18.00 and set an “overweight” rating for the company in a research note on Friday, October 11th. StockNews.com raised Amicus Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday. JPMorgan Chase & Co. lowered their target price on Amicus Therapeutics from $17.00 to $16.00 and set an “overweight” rating for the company in a report on Friday, August 16th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $20.00 price target on shares of Amicus Therapeutics in a research report on Friday, September 20th. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat.com, Amicus Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $17.13.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.